Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Excess primary intestinal lymphoproliferative disorders in IBD

This month's issue of the Inflammatory Bowel Diseases examines excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

News image

It remains to be shown whether inflammatory bowel disease (IBD) is associated with an increased risk of primary intestinal lymphoproliferative disorders.

Dr Laurent Beaugerie and colleagues from France assessed this risk in the CESAME French nationwide prospective observational cohort.
 
In all, 680 gastroenterologists enrolled 19,486 patients with IBD from 2004 to 2005, with follow-up that ended on 2007.

Available biopsy samples and surgical specimens from patients with primary intestinal lymphoproliferative disorders were centralized for review.

The incidence of primary intestinal lymphoproliferative disorders was 0.12 per 1000 patient-years
Inflammatory Bowel Disease

The reference incidence of primary intestinal lymphoproliferative disorders in the general population was obtained from the Côte d'Or registry, and was used as a comparator to assess the standardized incidence ratio.

The researchers explored the influence of thiopurine exposure in a nested case-control study.
 
In the CESAME population the crude incidence of primary intestinal lymphoproliferative disorders was 0.12 per 1000 patient-years, with a corresponding standardized incidence ratio of 17.5.

The research team found that the risk was highest in patients exposed to thiopurines, while it did not reach statistical significance in patients naïve to thiopurines.

The team noted that the odds ratio associated with ongoing thiopurine exposure was 2.97.

All 14 cases of primary intestinal lymphoproliferative disorders were non-Hodgkin's B-cell lymphoproliferative disorders, 79% occurred in males, 86% arose in IBD lesions, and 46% were Epstein–Barr virus-positive.

The researchers observed that 11 cases occurred in patients with Crohn's disease.

The team observed that the mean age at primary intestinal lymphoproliferative disorders diagnosis was 55 years, and the median time since IBD onset was 8 years.
 
Dr Beaugerie's team concludes, "Patients with IBD have an increased risk of developing primary intestinal lymphoproliferative disorders."

Inflamm Bowel Dis 2012: 18(11): 2063–2071
02 November 2012

Go to top of page Email this page Email this page to a colleague

 22 October 2014

Advanced search
 22 October 2014 
Liver fibrosis prognostic biomarkers in type-2 diabetes
 22 October 2014 
H pylori eradication with multiple drug resistance
 22 October 2014 
Early-TIPSS placement prevents rebleeding
 21 October 2014 
Scoring systems for critically ill cirrhotic patients
 21 October 2014 
Aspirin and NAFLD
 21 October 2014 
Alcohol and Barrett's
 20 October 2014 
Drug resistant H pylori eradication
 20 October 2014 
Adalimumab in secondary loss of response in Crohn's
 20 October 2014 
Omega-3 and colorectal cancer
 17 October 2014 
Colorectal testing utilization
 17 October 2014 
Fecal microbiota composition in postinfectious IBS
 17 October 2014 
Tumor necrosis factor-alpha inhibitors and pregnancy in IBD
 16 October 2014 
Risk of Barrett's esophagus
 16 October 2014 
Aspirin tablets and colorectal tumours
 16 October 2014 
Economic impact of IBS
 15 October 2014 
Achieving competency at colonoscopy
 15 October 2014 
Preparation for surgery in Crohn's
 15 October 2014 
Bowel preparations
 14 October 2014 
Colorectal testing utilization in commercially insured US adults
 14 October 2014 
Sustained response to infliximab
 14 October 2014 
IBD management during pregnancy
 13 October 2014 
Predicting PPI response in GERD-related cough
 13 October 2014 
Probiotics in IBS
 13 October 2014 
Use of azathioprine in IBD
 10 October 2014 
NAFLD in the Veterans Administration population
 10 October 2014 
Liver injury from herbals and dietary supplements
 10 October 2014 
Predictors for cecal insertion time
 09 October 2014 
Methotrexate-related liver disease and metabolic syndrome
 09 October 2014 
Biomarkers of acetaminophen overdose patients
 09 October 2014 
Postoperative adhesions in digestive surgery
 08 October 2014 
Feeding intervention in celiac disease infants
 08 October 2014 
Gluten introduction in high risk children
 08 October 2014 
Vitamin D and HCC
 07 October 2014 
Infliximab in pediatric perianal Crohn's
 07 October 2014 
Omega-3 and NAFLD
 07 October 2014 
Endoscopic submucosal dissection in the colorectum 
 06 October 2014 
Clinical indications for computed tomographic colonography
 06 October 2014 
Certolizumab pegol in the treatment of Crohn's
 06 October 2014 
Costs of telaprevir therapy for Hep C
 03 October 2014 
Depression and liver transplantation
 03 October 2014 
Orange juice intake during bowel preparation
 03 October 2014 
HCV and diabetes
 02 October 2014 
Predictive model of Hep C disease progression
 02 October 2014 
IPAA with or without preoperative radiation
 02 October 2014 
Person-to-person transmission of norovirus
 01 October 2014 
Prevention of postop Crohn's
 01 October 2014 
Cecal intubation time during colonoscopy
 01 October 2014 
Anti-TNFa therapies during pregnancy in IBD
 30 September 2014 
Autoimmune hepatitis
 30 September 2014 
Medication use in patients with chronic Hep C
 30 September 2014 
Gastric cancer according to H pylori infection status
 29 September 2014 
Drug exposure and microscopic colitis
 29 September 2014 
Peptic ulcer bleeding after PPI treatment
 29 September 2014 
Intestinal tuberculosis vs Crohn's disease
 26 September 2014 
5-aminosalicylates for the treatment of Crohn's
 26 September 2014 
Response to infliximab in paediatric perianal Crohn's
 26 September 2014 
Ondansetron for IBS with diarrhea
 25 September 2014 
Medical treatment and surgery rates in IBD
 25 September 2014 
Liver transplants for liver cancer
 25 September 2014 
Colorectal neoplasia among family members of patients with colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us